**Table II: ALDH1 expression and its significant association with clinicopathological parameters**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameters** | **ALDH1+(n=35)** | **ALDH1-(n=27)** | ***p* value** |
| **Mean tumour size(cm)** | 4.669 | 2.993 | **0.0001** |
| **T1 (n=9)** | 0 (0%) | 9 (33.3%) |
| **T2 (n=34)** | 19 (54.3%) | 15 (55.6%) |
| **T3 (n=17)** | 15 (42.8%) | 2 (7.4%) |
| **T4 (n=2)** | 1 (2.9%) | 1 (3.7%) |
| **Grade 1 (n=4)** | 0 (0%) | 4 (14.8%) | **0.0003** |
| **Grade 2 (n=45)** | 22 (62.9%) | 23 (85.2%) |
| **Grade 3 (n=13)** | 13 (37.1%) | 0 (0%) |
| **LVI present (n=39)** | 28 (80%) | 11 (40.8%) | **0.0036** |
| **LVI absent (n=23)** | 07 (20%) | 16 (59.2%) |
| **N0 (n=23)** | 6 (17.2%) | 17 (63%) | **0.0003** |
| **N1 (n=6)** | 3 (8.5%) | 3 (11.1%) |
| **N2 (n=16)** | 10 (28.6%) | 6 (22.2%) |
| **N3 (n=17)** | 16 (45.7%) | 1 (3.7%) |
| **NPI ≥5.4 (n=32)** | 26 (74.3%) | 6 (22.2%) | **0.0001** |
| **NPI <5.4 (n=30)** | 9 (25.7%) | 21 (77.8%) |
| **Stage I (n=9)** | 0 (0%) | 9 (33.3%) | **0.0003** |
| **Stage II (n=19)** | 9 (25.7%) | 10 (37%) |
| **Stage III (n=30)** | 22 (62.9%) | 8 (29.7%) |
| **Stage IV (n=4)** | 4 (11.4%) | 0 (0%) |
| **ER-(n=22)** | 22(62.8%) | 0 (0%) | **0.0001** |
| **ER+(n=40)** | 13(37.2%) | 27(100%) |
| **PR-(n=26)** | 23(65.7%) | 3(11.1%) | **0.0001** |
| **PR+(n=36)** | 12(34.3%) | 24(88.9%) |
| **HER2-(n=42)** | 17(48.6%) | 25(92.6%) | **0.0007** |
| **HER2+(n=20)** | 18(51.4%) | 2(7.4%) |
| **Ki-67 ≥20%(n=36)** | 29(82.9%) | 7(26%) | **0.0001** |
| **Ki-67 <20%(n=26)** | 6(17.1%) | 20(74%) |